Nippon Gases has signed a deal to acquire respiratory home therapies specialist Esteve Teijin Healthcare (ETH).
ETH is a joint venture between Corporación Quimico-Farmacéutica Esteve (CQFE) and Teijin Holdings Europe BV (Teijin) that was set up in 2009.
The business aligns with Nippon Gases’ existing business model, combining ETH’s knowledge in respiratory therapies with Nippon Gases’ field expertise.
Justin Corcho, CEO of Nippon Gases España, described the news as an historic combination, culturally and strategically, within the Spanish homecare market.
“We are excited to bring together both companies’ talent and capabilities and our shared commitment to providing the best patient care. With a proven track record of successfully and sustainably nurturing and growing acquired businesses, we are confident Nippon Gases is a natural home for the ETH business and employee.”
In Spain, Nippon Gases offers respiratory therapy services through its subsidiary Oximesa, and together with ETH, will cover more regions with minimal overlap.
Carlos Fina, CEO of ETH, said, “We are convinced that this agreement will be a great challenge for our company, representing a significant step forward in improving patient care and quality of life.”
The closing of the transaction remains subject to customary conditions and regulatory approvals.
European CO2 Summit 2025: Rotterdam
The conversation around carbon dioxide (CO2) is changing, with a focus on its value as part of a circular economy. Join The European CO2 Summit in Rotterdam this March to explore the future of the CO2 business in Europe and its alignment with decarbonisation efforts. Expect market insights, emerging technologies, panel discussions, and networking opportunities.
Learn more: https://bit.ly/Europeanco2summit2025-F
